Effects Of Androgen Therapy Combined With Transurethral Resection Of The Prostate In Metastatic Prostate Cancer

Purpose: To investigate the oncologic outcome of transurethral resection of theprostate (TURP) as a cytoreductive surgery in metastatic prostate cancer.Materials and methods:122Chinese males with newly diagnosed PCa, whoregistered in our hospital from January2007and February2012, were followed up fora median of15months (11-62months).44males received TURP and maximalandrogen blockade (MAB) as initial systematic therapy for a relief of bladder outletobstruction and other78received MAB alone. All the date had been collected werecompared between the two groups by statistical analysis.Results: Age at diagnosis, preoperative t-PSA, biopsy Gleason score, complication,etc, were comparable between the two groups. Patients who underwent a TURP hadlower PSA nadir (0.870ng/ml vs.1.739ng/ml in average, P=0.030) and had longertime of progression-free survival (PFS)(P<0.001). Disease-specific survival (DSS)and overall survival (OS) in the two groups did not reach statistical significance.Multiple regression analysis showed that only the treatment, the Gleason score and thelevels of preoperative t-PSA in the Serum were independent determinants ofPFS,the age and the Gleason score were independent determinants of DSS, the ageand complication were independent determinants of OS in these patients, respectively.Conclusions: TURP seemed to be effective for hormone therapy in metastaticprostate cancer and resulted in improvements in progression-free survival rate.